Whole-Body Dosimetry for Targeted Radionuclide Therapy Using Spectral Analysis
- 1 February 2005
- journal article
- research article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 20 (1) , 66-71
Abstract
The whole-body dose (WBD) is routinely calculated for targeted radionuclide therapy (TRT). The aim of this work was to investigate the feasibility of using spectral analysis (SA) for the automatic delineation of decay phases, and consequently, the calculation of the WBD given a whole-body (WB) time-activity curve (TAC). SA characterizes the TAC as an arbitrary sum of exponential functions determined by fitting the data with a non-negative least-squares (NNLS) algorithm. The cumulated activity (CA) is calculated analytically as the integral of the fitted curve while the number of phases describing the kinetics of the radiopharmaceutical and the half-lives of the phases can be determined from the spectrum. The uncertainty associated with the estimation of the WBD can be obtained using bootstrap techniques. SA was applied to WB TACs from 186Re-HEDP and 131I-mIBG therapies. The results were compared to results obtained using a semiempirical method and showed good agreement in the calculated WBDs. Bootstrapping with resampling on a subset of patients from the two therapies showed much larger coefficient-ofvariation (CV) for the 186Re-HEDP TACs than for the 131I-mIBG therapies. We concluded that SA provides a fast, accurate, and reproducible method to obtain WBDs and accurate estimates of the parameters describing the radiotracer kinetics. The method could be extended to other dosimetric applications.Keywords
This publication has 6 references indexed in Scilit:
- A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186 Re-HEDP treatment of skeletal metastases from prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapyPhysics in Medicine & Biology, 2002
- High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to boneBritish Journal of Cancer, 2002
- Evaluation of compartmental and spectral analysis models of [/sup 18/F]FDG kinetics for heart and brain studies with PETIEEE Transactions on Biomedical Engineering, 1998
- Radiation dosimetry for therapy of neuroblastomaPhysics in Medicine & Biology, 1996
- Spectral Analysis of Dynamic PET StudiesJournal of Cerebral Blood Flow & Metabolism, 1993